BioSpace News Archive

The Company will host a conference call and webcast at 8:45 a.m. ET to discuss third quarter 2017 financial results and provide a business update.

The data is published in the Journal of the American College of Cardiology (JACC).

To date, four lead candidates have been selected based on in vitro and animal preclinical studies, stability, and manufacturing feasibility. Additional animal efficacy and toxicology testing of these lead candidates is underway, and CytRx is anticipating several milestones associated with the LADR candidates in the upcoming months and quarters.

22nd Century announced today the hiring of James E. Swauger, Ph.D., as the Company’s Senior Vice President of Science and Regulatory Affairs.

The live and archived webcast can be accessed via the company’s website

Cash, cash equivalents and short-term investments, as of Sept. 30, 2017, were $27.5 million.

Seres Therapeutics announced that management will host a conference call and live audio webcast on November 8, 2017 at 8:00 a.m. ET to discuss third quarter 2017 results and provide a general business update.

Bristol-Myers Squibb today confirmed that 34 abstracts related to ORENCIA (abatacept) and the Company’s immunoscience pipeline

The company reported revenue of $1.3 billion for the third quarter of 2017, an increase of 9% compared with the third quarter of 2016.

[02-November-2017] NEW HAVEN, Conn., Nov. 2, 2017 /PRNewswire/ -- Arvinas LLC, a private biotechnology company creating a new class of small molecule drugs based on protein degradation, today announced the selection of its first candidate for clinical development as a novel treatment for metastatic castration-resistant prostate cancer (mCRPC). ARV-110 is an orally bioavailable small molecu